Anti-Aging · Brain Health · Cellular Energy · Clinical Insights · CoQ10 · Longevity · Mitochondria · Neurobiologix · Pharmacist Reviewed · pillar-clinical-evidence-library · pillar-healthy-aging-cellular-health · pillar-nutrition-supplements · PQQ · Supplements ·May 25, 2026

CoQ10 and PQQ: The Mitochondrial Support Stack — A Pharmacist’s Evidence Review

Dai Tran, PharmD, MBA, B.S.

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

The Clinical Question

CoQ10 (Coenzyme Q10) and PQQ (Pyrroloquinoline Quinone) are both sold for mitochondrial and energy support, and they are frequently combined in supplement formulas. They operate through different proposed mechanisms. CoQ10 has a well-established role in cellular energy production and a substantial human clinical literature, although the strength and consistency of evidence vary considerably by indication. PQQ has interesting preclinical mechanisms but a much more limited human clinical trial record. This article reviews what the research actually supports for each.

What the Evidence Does — and Does Not — Establish

CoQ10

Established biology: Essential electron carrier in mitochondrial energy metabolism; fat-soluble antioxidant protecting mitochondrial membranes.
Human clinical evidence: Substantial, but varies by indication. Important randomized evidence exists in chronic heart failure; evidence for blood pressure and statin-associated muscle symptoms is more mixed.
Not established: Universal energy enhancement or general “mitochondrial optimization” in healthy adults without specific clinical indications.

PQQ

Established chemistry/biology: PQQ is a redox-active compound with demonstrated biological activity in experimental systems.
Preclinical: Mitochondrial-biogenesis mechanisms involving CREB and PGC-1α signaling have been demonstrated in cell culture.
Preliminary human evidence: Small trials evaluating cognition and oxidative stress markers; one human exercise RCT detected a PGC-1α molecular signal without functional performance benefit.
Not established: That oral PQQ meaningfully increases mitochondrial biogenesis, improves longevity, or produces broad mitochondrial health benefits in humans. The gap between “activates mitochondrial-biogenesis signaling in mouse hepatocyte cells” and “creates new mitochondria in humans who take oral PQQ” has not been bridged by human clinical research.

CoQ10 — Role in Cellular Energy Production

CoQ10 is a fat-soluble compound found naturally in every cell, with the highest concentrations in energy-demanding tissues such as the heart, liver, kidneys, and brain. It functions as an electron carrier in the mitochondrial electron transport chain, contributing to ATP synthesis. It also acts as a fat-soluble antioxidant, protecting mitochondrial membranes from oxidative damage.

CoQ10 synthesis declines with age, and statin medications further reduce CoQ10 availability by inhibiting the HMG-CoA reductase (mevalonate) pathway shared with CoQ10 biosynthesis.

CoQ10 Human Clinical Evidence

Heart failure: The Q-SYMBIO trial (Mortensen et al., PMID: 25282031) randomized 420 patients with moderate-to-severe chronic heart failure to CoQ10 300mg/day or placebo for 2 years. CoQ10 significantly reduced the primary long-term composite endpoint of major adverse cardiovascular events (15% vs 26%, HR 0.50) and all-cause mortality (10% vs 18%). Short-term 16-week endpoints were not significantly different. Q-SYMBIO is an important long-term randomized trial supporting CoQ10 as adjunctive therapy in chronic heart failure; it should be considered alongside other trials and systematic reviews in this area, and CoQ10 should not replace guideline-directed heart-failure therapy.
Blood pressure: CoQ10 has been studied for possible blood-pressure effects, but findings across the evidence base are inconsistent and clinically meaningful blood-pressure lowering has not been established. The available evidence, including NCCIH’s current summary, suggests CoQ10 probably does not have a meaningful effect on blood pressure.
Statin-associated muscle symptoms: Statins can reduce circulating CoQ10 through inhibition of the mevalonate pathway. Whether CoQ10 supplementation meaningfully improves statin-associated muscle symptoms remains uncertain. A 2025 systematic review and meta-analysis (Kovacic et al., PMID: 41158831) of seven RCTs and 389 participants found a statistically significant pooled reduction in pain intensity, while individual trial results were inconsistent. CoQ10 may be reasonable to discuss in selected patients, but persistent muscle symptoms warrant clinical evaluation rather than supplementation alone.
Ubiquinone vs. ubiquinol: CoQ10 exists in two forms — ubiquinone (oxidized) and ubiquinol (reduced). Some evidence suggests ubiquinol may have greater bioavailability, particularly in older adults. The clinical significance of the difference between forms is debated.

Doses studied in clinical trials: Typically 100–300mg/day for general use; 300mg/day (100mg three times daily) in the Q-SYMBIO heart failure trial.

PQQ — What the Evidence Shows

PQQ is a redox-active compound found in trace amounts in some foods. It has been studied for antioxidant activity and possible effects on mitochondria and cognitive function. Much of the mechanistic work — including proposed activation of PGC-1α and CREB signaling — comes from cell culture and animal studies. Whether these mechanisms translate meaningfully to clinical outcomes in humans from oral supplementation is not well established.

PQQ Human Clinical Evidence

A placebo-controlled trial (Itoh et al., PMID: 26782228) examining PQQ 20mg/day for 12 weeks in middle-aged and older adults found improvements in composite cognitive test scores. The study was small and short-duration; it does not establish PQQ as a treatment for cognitive decline.
A human randomized exercise trial (Hwang et al., PMID: 31860387) evaluated PQQ 20mg/day during 6 weeks of endurance training in untrained men. PQQ increased skeletal-muscle PGC-1α protein — a molecular signal consistent with the preclinical mitochondrial-biogenesis hypothesis — but did not improve aerobic performance or body composition compared with placebo. This is scientifically informative: a molecular signal was detected, but it did not translate into functional performance benefit in this trial.
Small human studies have examined PQQ’s effects on oxidative stress markers and sleep quality, with some positive signals. These studies are too limited to draw strong conclusions.
The human clinical trial literature for PQQ is considerably smaller and less rigorous than for CoQ10. The preclinical mitochondrial-biogenesis mechanisms — while scientifically interesting — have not been confirmed in human RCTs.

Doses studied in human trials: Most trials have used 20mg/day.

Comparing the Evidence

Feature	CoQ10	PQQ
Primary Role	Electron carrier in ATP synthesis; fat-soluble antioxidant	Redox-active compound; preclinical mitochondrial and neuroprotective mechanisms
Human Clinical Evidence	Substantial; varies by indication; important randomized evidence in heart failure	Limited; small early trials in cognition and oxidative stress; one exercise RCT with molecular signal but no functional benefit
Mitochondrial Biogenesis	Not a primary mechanism	Proposed in preclinical research; molecular signal detected in one human RCT but without functional performance benefit
Statin Pathway Depletion	Yes — statins inhibit the mevalonate pathway shared with CoQ10 biosynthesis	Not applicable
Safety Profile	Well-established; warfarin interaction uncertain — monitor INR	Generally well-tolerated at studied doses (20mg/day); long-term data limited

Featured Product: Neurobiologix® Mito Cell PQQ™

Neurobiologix® Mito Cell PQQ™ (60 Capsules)

A multi-ingredient mitochondrial support formula combining PQQ (20mg), CoQ10 (75mg), NADH (20mg), Acetyl-L-Carnitine, Resveratrol, Quercetin, Vitamin C, Zinc, and L-Ornithine per label specifications. Formulated by Kendal Stewart, MD. Verify current label for up-to-date ingredient and dose information.

Pharmacist’s Note: As a PharmD, I discuss this formula with patients looking for a multi-ingredient mitochondrial support product. It combines CoQ10 — which has a substantial human clinical evidence base — with PQQ and several other compounds commonly studied in mitochondrial, antioxidant, or cellular-energy research. Evidence for each ingredient and dose should be considered separately, and clinical evidence for the finished combination itself should not be assumed from studies of its individual ingredients. Patients on warfarin or blood pressure medications should discuss with their pharmacist before starting.

Safety & Medication Considerations

Statins (CoQ10): Statins inhibit the mevalonate pathway shared with CoQ10 biosynthesis. Whether CoQ10 supplementation meaningfully reduces statin-associated symptoms varies across trials — some show benefit, others do not. Discuss with your pharmacist or prescriber, especially if you are experiencing muscle symptoms that warrant clinical evaluation.
Warfarin (CoQ10): Case reports have suggested that CoQ10 may reduce warfarin’s anticoagulant effect, although a small randomized crossover study did not confirm a clinically significant interaction. Because changes in anticoagulation could be clinically important, patients taking warfarin should discuss CoQ10 with their anticoagulation provider and have INR monitored when appropriate after starting or stopping supplementation.
Blood pressure medications (CoQ10): CoQ10 has been studied for possible blood-pressure effects, but findings across the evidence base are inconsistent and clinically meaningful blood-pressure lowering has not been established. Patients taking antihypertensive medications should review supplementation with their pharmacist or prescriber.
Chemotherapy: CoQ10’s antioxidant properties may theoretically interact with some oxidative chemotherapy regimens. Consult your oncology team before use during active cancer treatment.
PQQ: No clinically significant drug interactions have been established at standard doses (20mg/day). Generally well-tolerated in short-term trials.

Who May Consider Discussing CoQ10 or PQQ?

Adults interested in discussing CoQ10 or PQQ supplementation in the context of the available mitochondrial, cardiovascular, or cognitive research with a pharmacist or healthcare professional.
Adults with chronic heart failure who are interested in adjunctive CoQ10 — discuss with their cardiologist before starting; CoQ10 should not replace guideline-directed heart-failure therapy.
Adults on statin medications experiencing muscle symptoms — discuss CoQ10 with your pharmacist or prescriber; evidence for benefit is mixed.
Adults interested in early PQQ cognitive or mitochondrial research who want to discuss the evidence with a pharmacist before starting.

Patients with significant medical conditions, cancer, or those taking prescription medications should discuss supplementation with their treating clinician before use. CoQ10 and PQQ are not substitutes for established medical treatment.

Selected Key Studies

Evidence labels: HUMAN RCT = randomized controlled trial | SYSTEMATIC REVIEW = structured evidence synthesis | PRECLINICAL = animal or in vitro research

HUMAN RCT Mortensen SA, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641–649. PMID: 25282031. DOI: 10.1016/j.jchf.2014.06.008.
RCT (n=420); CoQ10 300mg/day for 2 years significantly reduced the primary long-term composite endpoint of major adverse cardiovascular events (15% vs 26%, HR 0.50) and all-cause mortality (10% vs 18%) in patients with moderate-to-severe heart failure. Short-term (16-week) endpoints were not significantly different. An important long-term trial supporting CoQ10 as adjunctive therapy in chronic heart failure; should be considered alongside other trials and systematic reviews in this area.
SYSTEMATIC REVIEW — MIXED EVIDENCE Kovacic S, Habicht SD, Eckert GP. Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis. J Nutr Sci. 2025;14:e72. PMID: 41158831. DOI: 10.1017/jns.2025.10043.
Systematic review and meta-analysis of seven randomized controlled trials (389 participants) evaluating CoQ10 for statin-associated muscle symptoms. Pooled analysis found a modest reduction in pain intensity, but individual trial results were inconsistent. The findings suggest possible benefit while illustrating the continuing uncertainty in this evidence base.
HUMAN RCT Itoh Y, Hine K, Miura H, Uetake T, Nakano M, Takemura N, Sakatani K. Effect of the Antioxidant Supplement Pyrroloquinoline Quinone Disodium Salt (BioPQQ™) on Cognitive Functions. Adv Exp Med Biol. 2016;876:319–325. PMID: 26782228. DOI: 10.1007/978-1-4939-3023-4_40.
Small placebo-controlled trial (n=41) in middle-aged and older adults; PQQ 20mg/day for 12 weeks was associated with improvements in composite cognitive test scores. The study was small and short-duration; it does not establish PQQ as a treatment for cognitive decline.
HUMAN RCT — MOLECULAR SIGNAL, NO FUNCTIONAL BENEFIT Hwang PS, Machek SB, Cardaci TD, Wilburn DT, Kim CS, Suezaki ES, Willoughby DS. Effects of Pyrroloquinoline Quinone (PQQ) Supplementation on Aerobic Exercise Performance and Indices of Mitochondrial Biogenesis in Untrained Men. J Am Coll Nutr. 2020;39(6):547–556. PMID: 31860387. DOI: 10.1080/07315724.2019.1705203.
Randomized trial evaluating PQQ 20mg/day during 6 weeks of endurance training in untrained men. PQQ increased skeletal-muscle PGC-1α protein — a molecular signal consistent with the preclinical mitochondrial-biogenesis hypothesis — but did not improve aerobic performance or body composition compared with placebo. Scientifically important: a molecular signal was detected without translating into functional performance benefit.
PRECLINICAL Chowanadisai W, et al. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1α expression. J Biol Chem. 2010;285(1):142–152. PMID: 19861415. DOI: 10.1074/jbc.M109.030130.
Cell culture study (mouse Hepa1-6 hepatocytes) demonstrating PQQ activated CREB phosphorylation and increased PGC-1α expression, consistent with mitochondrial biogenesis signaling. These are preclinical mechanistic findings. Whether oral PQQ supplementation stimulates mitochondrial biogenesis in humans has not been established in clinical trials.
SYSTEMATIC REVIEW — METHODOLOGICALLY LIMITED Rosenfeldt FL, et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007;21(4):297–306. PMID: 17287847. DOI: 10.1038/sj.jhh.1002138.
Early meta-analysis of 12 studies on CoQ10 and blood pressure; only 3 were RCTs, plus one crossover and 8 open-label studies. Methodologically limited by current standards. Included for historical context; current evidence, including NCCIH’s summary, suggests CoQ10 probably does not have a meaningful effect on blood pressure.

Pharmacist’s Perspective

As a PharmD, I discuss CoQ10 and PQQ differently depending on a patient’s goals and clinical context. CoQ10 has substantially more human clinical evidence than PQQ, including randomized research in chronic heart failure and extensive — but sometimes conflicting — research in areas such as blood pressure and statin-associated muscle symptoms. PQQ is an interesting early-stage compound; the preclinical mechanisms are scientifically compelling, and one human exercise RCT detected a PGC-1α molecular signal, but functional benefit was not demonstrated. I describe PQQ honestly as investigational in terms of clinical outcome evidence in humans. I do not present their combined use as established synergy. I always review a patient’s full medication list before recommending either. Free PharmD consultation: (408) 622-8068.

Frequently Asked Questions

Q: Should I take CoQ10 as ubiquinone or ubiquinol?
A: Ubiquinol may offer greater bioavailability, particularly in older adults. The clinical significance of the difference between forms is debated. Discuss with your pharmacist based on your specific situation.

Q: Can I take CoQ10 and PQQ together?
A: They have no known interactions with each other. Whether combining them produces additional clinical benefit compared to either alone has not been studied in human trials.

Q: I’m on a statin. Should I take CoQ10?
A: Statins inhibit the mevalonate pathway shared with CoQ10 biosynthesis. Whether CoQ10 supplementation meaningfully reduces statin-associated symptoms varies across trials — some show benefit, others do not. Discuss with your pharmacist or prescriber, especially if you are experiencing muscle symptoms that warrant clinical evaluation.

Q: How long before I might notice effects from CoQ10?
A: Clinical trials evaluating CoQ10 typically run 8 weeks or longer before assessing outcomes. Individual responses vary considerably.

CoQ10 and PQQ: The Mitochondrial Support Stack — A Pharmacist’s Evidence Review

The Clinical Question